N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

High-definition Transcranial Electrical Stimulation for Upper Extremity Rehabilitation

Sponsor: National Taiwan University Hospital • ClinicalTrials.gov ID: NCT06409143

Registry updated: 2026-08-20
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Upper limb hemiparesis is the most common sequelae in patients, severely impacting their independence and quality of life. Transcranial electrical stimulation (tCES) is a non-invasive and safe treatment, which uses a low direct current or alternating current to change the excitability of the cerebral cortex. It can induces long-term potentiation-like or long-term depression-like effects, thereby modulating the cortical excitability. In recent years, researchers have developed high-definition (HD) devices, which integrate high definition ring electrode configurations and incorporate direct current with theta burst stimulation waveforms. Diverging from traditional transcranial direct current stimulation (tDCS), which applies weak currents (0.5-2 mA) through two large sponge electrodes (25\~35 cm\^2) externally to the scalp for widespread non-specific cortical stimulation, HD-tES employs an array of small-area electrodes (1 cm\^2) to control current distribution over localized cortical regions, thereby enhancing spatial accuracy. However, there is a lack of studies validating the optimal waveform for HD-tES, as well as clinical evidence in subacute stroke populations. The optimal unilateral versus bilateral stimulation modes and their neurological mechanisms for stroke rehabilitation also remain uncertain.

Interventions

  • HD-tES (Device)
    The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.
  • Sham HD-tES (Device)
    The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.
  • UE rehabilitation (Other)
    Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 60 minutes each time, 5 times a week, lasting for 3 weeks.
  • HD-tES (Bilateral) (Device)
    The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds.

Eligibility criteria

Inclusion Criteria: \- Sub-Project 1 (Healthy) 1. Adults aged 18 and above. 2. Confirmed right-handedness using the Edinburgh Handedness Inventory. Sub-Project 1 (Post-stroke patients) 1. Aged 18 and above. 2. Diagnosed with stroke. 3. Post-stroke for more than 6 months. 4. Unilateral hemiparesis. Sub-Project 2 (Subacute-stroke patients) 1. Aged 18 and above. 2. Diagnosed with stroke. 3. Stroke occurred between 7 days to 6 months ago. 4. Unilateral hemiparesis. 5. Degree of recovery for proximal and distal movements of the affected upper limb is Brunnstrom stage III to V. 6. No severe muscle spasticity in any segments of the affected upper limb (Modified Ashworth Scale ≤ 2). Exclusion Criteria: \- Sub-Project 1 (Healthy) 1. History of neurological disorders (e.g., stroke, brain tumor, epilepsy), psychiatric disorders (e.g., substance abuse, major depression, schizophrenia, bipolar disorder), or musculoskeletal disorders of the upper limb. 2. Contraindications to transcranial electrical stimulation, including history of epilepsy, atrial fibrillation, presence of metal implants, cardiac pacemakers, convexity skull defects, or increased intracranial pressure. 3. Skin allergies, contact dermatitis, abnormal pain, hypersensitivity to pain, wounds, or ulcers on the head. 4. Participation in other invasive or non-invasive brain stimulation research studies. 5. Pregnancy or lactating women. (If female, must be postmenopausal or surgically sterilized. Fertile women must have a negative pregnancy test result. Fertile female patients engaging in heterosexual intercourse, as well as fertile male patients with fertile female partners, must agree to use effective contraception during the trial period and for 4 months after the last dose of the investigational drug, such as oral contraceptives, dual barrier methods, intrauterine devices, or abstain from sexual intercourse during this period; non-fertile women are those who have undergone bilateral oophorectomy or are postmenopausal.) 6. History of alcohol or substance abuse. 7. Damaged skin at the stimulation site, electrode contact, or device wearing site. 8. Long-term use of central nervous system affecting medications (such as antidepressants, sedatives) or other medications that may affect seizure threshold. 9. Other conditions deemed unsuitable for transcranial electrical or magnetic stimulation by a physician. 10. Affiliation with any research institution/execution unit (e.g., students from NTU, Taipei Medical University). Sub-Project 1 (Post-stroke patients) 1. Contraindications to transcranial electrical stimulation include a history of epilepsy, atrial fibrillation, presence of metal implants, cardiac pacemakers, convexity skull defects, or increased intracranial pressure. 2. Skin allergies, contact dermatitis, abnormal pain, hypersensitivity to pain, wounds, or ulcers on the head. 3. Severe neurological or psychiatric disorders other than stroke (such as major depression, schizophrenia, substance abuse, organic brain diseases, Parkinson's disease, brain tumors). 4. Use of medications that may lower the seizure threshold. 5. Undergoing other invasive or non-invasive brain stimulation therapies. 6. Pregnancy or lactating women. (If female, must be postmenopausal or surgically sterilized. Fertile women must have a negative pregnancy test result. Fertile female patients engaging in heterosexual intercourse, as well as fertile male patients with fertile female partners, must agree to use effective contraception during the trial period and for 4 months after the last dose of the investigational drug, such as oral contraceptives, dual barrier methods, intrauterine devices, or abstain from sexual intercourse during this period; non-fertile women are those who have undergone bilateral oophorectomy or are postmenopausal.) 7. History of alcohol or substance abuse. 8. Damaged skin at the stimulation site, electrode contact, or device wearing site. 9. Long-term use of central nervous system affecting medications (such as antidepressants, sedatives) or other medications that may affect seizure threshold. 10. Other conditions deemed unsuitable for transcranial electrical or magnetic stimulation by a physician. Sub-Project 2 (Subacute-stroke patients) 1. Contraindications to transcranial electrical stimulation include a history of epilepsy, atrial fibrillation, presence of metal implants, cardiac pacemakers, convexity skull defects, or increased intracranial pressure. 2. Skin allergies, contact dermatitis, abnormal pain, hypersensitivity to pain, wounds, or ulcers on the head. 3. Severe neurological or psychiatric disorders other than stroke (such as major depression, schizophrenia, substance abuse, organic brain diseases, Parkinson's disease, brain tumors). 4. Use of medications that may lower the seizure threshold. 5. Other muscle and joint problems affecting upper limb function, such as joint contractures, rheumatoid arthritis, myositis ossificans. 6. Severe cognitive impairment or receptive or global aphasia making it difficult to understand instructions. 7. Hemineglect (including visual, auditory, or sensory neglect). 8. Undergoing other invasive or non-invasive brain stimulation therapies. 9. Pregnancy or lactating women. (If female, must be postmenopausal or surgically sterilized. Fertile women must have a negative pregnancy test result. Fertile female patients engaging in heterosexual intercourse, as well as fertile male patients with fertile female partners, must agree to use effective contraception during the trial period and for 4 months after the last dose of the investigational drug, such as oral contraceptives, dual barrier methods, intrauterine devices, or abstain from sexual intercourse during this period; non-fertile women are those who have undergone bilateral oophorectomy or are postmenopausal.) 10. History of alcohol or substance abuse. 11. Damaged skin at the stimulation site, electrode contact, or device wearing site. 12. Long-term use of central nervous system affecting medications (such as antidepressants, sedatives) or other medications that may affect seizure threshold. 13. Other conditions deemed unsuitable for transcranial electrical or magnetic stimulation by a physician.

Conditions

Stroke

Locations

  • National Taiwan University Hospital Hsin-Chu Branch — Hsinchu, Taiwan
  • New Taipei City Tucheng Hospital — New Taipei City, Taiwan
  • National Taiwan University Hospital — Taipei, Taiwan
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record